ViaCyte's Stem Cell-Derived Treatment For Type 1 Diabetes Shows Promising Results In Two Published Studies [TheStreet.com]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: TheStreet.com
SAN DIEGO, Dec. 2, 2021 /PRNewswire/ --, a clinical-stage regenerative medicine company focused on developing novel cell replacement therapies to address diseases with significant unmet needs, announced publication of promising preliminary results of an ongoing, first-in-human Phase 1/2 study demonstrating that its stem cell-derived therapy can produce insulin in people with severe type 1 diabetes (T1D). The findings were published today in and. "The data from these papers represent a significant scientific advance," said Cell Reports Medicine study lead author James Shapiro, MD PhD, Canada Research Chair and Director of the Islet Transplant Program at the University of Alberta, Canada. "It is the first reported evidence that differentiated stem cells implanted in patients can generate meal-regulated insulin secretion, offering real hope for the incredible potential of this treatment." The Cell Reports Medicine paper reports on 17 patients who were implanted with ViaCyte's PEC-Direc
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Biotech Roundtable: Is CRISPR all it's cracked up to be? [Seeking Alpha]Seeking Alpha
- Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape [Seeking Alpha]Seeking Alpha
- CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know [Yahoo! Finance]Yahoo! Finance
- ARKG: Massive Potential, But Not Worth The Risk Yet For These 3 Reasons [Seeking Alpha]Seeking Alpha
- GNOM: Genomics Still Waiting For Its 'ChatGPT' Moment [Seeking Alpha]Seeking Alpha
CRSP
Earnings
- 2/21/24 - Beat
CRSP
Sec Filings
- 3/27/24 - Form PRE
- 3/22/24 - Form 4
- 3/22/24 - Form 4
- CRSP's page on the SEC website